These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 14760893)

  • 1. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
    Kirk O; Lundgren JD; Pedersen C; Mathiesen LR; Nielsen H; Katzenstein TL; Obel N; Gerstoft J
    Antivir Ther; 2003 Dec; 8(6):595-602. PubMed ID: 14760893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
    Ananworanich J; Hill A; Siangphoe U; Ruxrungtham K; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Nuesch R; Cooper DA; Hirschel B;
    Antivir Ther; 2005; 10(6):761-7. PubMed ID: 16218176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
    Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
    Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B;
    Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
    Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME
    Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
    Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
    Plana M; Ferrer E; Martínez C; Podzamczer D; García F; Maleno MJ; Barceló JJ; García A; Barberá MJ; Lacarcel M; Miró JM; Gallart T; Gatell JM
    Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
    Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T
    J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
    Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J
    HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy.
    Rockstroh JK; Altfeld M; Kupfer B; Kaiser R; Fätkenheuer G; Salzberger B; Schneweis KE; Spengler U
    Eur J Med Res; 1999 Jul; 4(7):271-4. PubMed ID: 10425264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
    Gartland M;
    Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
    HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.